MIRIKIZUMAB IMPROVES PATIENT ASSESSMENT OF DISEASE SEVERITY AND CHANGE IN DISEASE ACTIVITY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE

David T. Rubin  ¹     Paul F. Pollock  ²     Theresa Hunter     Mingyang Shan     Lai Shan Chan     Deanilee Deckard    
¹ University of Chicago Medicine, Chicago, United States
² Eli Lilly and Company, Indianapolis, United States

Topic
IBD, Immunology, Paediatrics

Session
Patient outcomes in IBD trials

Conference
UEG Week Virtual 2021

Citation
United European Gastroenterology Journal 2021; 9 (Supplement 8)